Quinine topical nasal spray - GeneOne Life Science
Alternative Names: GLS-1200Latest Information Update: 12 Oct 2022
Price :
$50 *
At a glance
- Originator GeneOne Life Science
- Class Antimalarials; Antiprotozoals; Cinchona alkaloids; Muscle relaxants; Non-opioid analgesics; Quinolines; Quinuclidines; Small molecules
- Mechanism of Action G protein-coupled receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II COVID 2019 infections; Rhinosinusitis
Most Recent Events
- 12 Oct 2022 Phase-II clinical trials in Rhinosinusitis (Prevention) in USA (Intranasal) (GeneOne Life Science pipeline, October 2022)
- 07 Oct 2022 Quinine topical nasal spray is still in phase II trials for COVID-2019 infections in USA (NCT04408183) (GeneOne Life Science pipeline, October 2022)
- 29 Sep 2022 GeneOne Life Science terminates a phase II trial in COVID-2019 infections (Prevention) in USA (Intranasal) due to no longer enrolling (NCT04408183)